Adaptimmune says it's (nearly) ready to head to the FDA with TCR cancer therapy
Six months after an initial reveal at ASCO, Adaptimmune is back in the limelight with new data Thursday. And the company believes it now has enough to go to regulators for what would be the first-ever TCR therapy.
The biotech’s afami-cel program put out updated figures Thursday morning with researchers noting as of Sept. 1, 16 of 47 patients saw their tumors shrink while on the experimental treatment. It’s good enough for a 34% overall response rate and, while lower than the May update of 39%, makes Adaptimmune confident enough to say the study will reach its primary endpoint.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.